Chest MRI of patients with COVID-19

Current Diagnostic Techniques for Pneumonia: A Scoping Review

Community-acquired pneumonia is one of the most lethal infectious diseases, especially for infants and the elderly. Given the variety of causative agents, the accurate early detection of pneumonia is an active research area. To the best of our knowledge, scoping reviews on diagnostic techniques for pneumonia are lacking. In this scoping review, three major electronic databases were searched and the resulting research was screened. We categorized these diagnostic techniques into four classes (i.e., lab-based methods, imaging-based techniques, acoustic-based techniques, and physiological-measurement-based techniques) and summarized their recent applications. Major research has been skewed towards imaging-based techniques, especially after COVID-19. Currently, chest X-rays and blood tests are the most common tools in the clinical setting to establish a diagnosis; however, there is a need to look for safe, non-invasive, and more rapid techniques for diagnosis. Recently, some non-invasive techniques based on wearable sensors achieved reasonable diagnostic accuracy that could open a new chapter for future applications. Consequently, further research and technology development are still needed for pneumonia diagnosis using non-invasive physiological parameters to attain a better point of care for pneumonia patients.

COVID-19 diagnostics: Molecular biology to nanomaterials

The SARS-CoV-2 pandemic has claimed around 6.4 million lives worldwide. The disease symptoms range from mild flu-like infection to life-threatening complications. The widespread infection demands rapid, simple, and accurate diagnosis. Currently used methods include molecular biology-based approaches that consist of conventional amplification by RT-PCR, isothermal amplification-based techniques such as RT-LAMP, and gene editing tools like CRISPR-Cas. Other methods include immunological detection including ELISA, lateral flow immunoassay, chemiluminescence, etc. Radiological-based approaches are also being used. Despite good analytical performance of these current methods, there is an unmet need for less costly and simpler tests that may be performed at point of care. Accordingly, nanomaterial-based testing has been extensively pursued. In this review, we discuss the currently used diagnostic techniques for SARS-CoV-2, their usefulness, and limitations. In addition, nanoparticle-based approaches have been highlighted as another potential means of detection. The review provides a deep insight into the current diagnostic methods and future trends to combat this deadly menace.

SARS-CoV-2 severity classification from plasma sample using confocal Raman spectroscopy

The world is on the brink of facing coronavirus's (COVID-19) fourth wave as the mutant forms of viruses are escaping neutralizing antibodies in spite of being vaccinated. As we have already witnessed that it has encumbered our health system, with hospitals swamped with infected patients observed during the viral outbreak. Rapid triage of patients infected with SARS-CoV-2 is required during hospitalization to prioritize and provide the best point of care. Traditional diagnostics techniques such as RT-PCR and clinical parameters such as symptoms, comorbidities, sex and age are not enough to identify the severity of patients. Here, we investigated the potential of confocal Raman microspectroscopy as a powerful tool to generate an expeditious blood-based test for the classification of COVID-19 disease severity using 65 patients plasma samples from cohorts infected with SARS-CoV-2. We designed an easy manageable blood test where we used a small volume (8 μl) of inactivated whole plasma samples from infected patients without any extra solvent usage in plasma processing. Raman spectra of plasma samples were acquired and multivariate exploratory analysis PC-LDA (principal component based linear discriminant analysis) was used to build a model, which segregated the severe from the non-severe COVID-19 group with a sensitivity of 83.87%, specificity of 70.60% and classification efficiency of 76.92%. Among the bands expressed in both the cohorts, the study led to the identification of Raman fingerprint regions corresponding to lipids (1661, 1742), proteins amide I and amide III (1555, 1247), proteins (Phe) (1006, 1034), and nucleic acids (760) to be differentially expressed in severe COVID-19 patient's samples. In summary, the current study exhibits the potential of confocal Raman to generate simple, rapid, and less expensive blood tests to triage the severity of patients infected with SARS-CoV-2.

Role of MRI in the Evaluation of Pulmonary Sequel Following COVID-19 Acute Respiratory Distress Syndrome (ARDS)

To evaluate the role of magnetic resonance imaging (MRI) chest as an alternative modality to CT chest for follow-up of patients recovered from severe COVID-19 acute respiratory distress syndrome (ARDS). A total of 25 subjects (16 [64%] men; mean age 54.84 years ± 12.35) who survived COVID-19 ARDS and fulfilled the inclusion criteria were enrolled prospectively. All the patients underwent CT and MRI chest (on the same day) at 6-weeks after discharge. MRI chest was acquired on 1.5T MRI using HASTE, BLADE, VIBE, STIR, and TRUFI sequences and evaluated for recognition of GGOs, consolidation, reticulations/septal thickening, parenchymal bands, and bronchial dilatation with CT chest as the gold standard. The differences were assessed by independent-sample t-test and Mann-Whitney U test. P-value of less than 0.05 was taken significant. There was a strong agreement (k = 0.8-1, P<0.01) between CT and MRI chest. On CT, the common manifestations were: GGOs (n=24, 96%), septal thickening/reticulations (n=24, 96%), bronchial dilatation (n=16, 64%), parenchymal bands (n=14, 56%), pleural thickening (n=8, 32%), consolidation (n=4, 16%) and crazy-paving (n=4, 16%). T2W HASTE, T2W BLADE, and T1 VIBE sequences showed 100% (95% CI, 40-100) sensitivity and 100% (95% CI, 3-100) specificity for detecting GGOs, septal thickening/reticulations, pleural thickening, consolidation, and crazy-paving. The overall sensitivity of MRI for detection of bronchial dilatation and parenchymal bands were 88.9% (95% CI, 77-100) and 92.9% (95% CI, 66-100), respectively; and specificity was 100% (95% CI, 29-100) for both findings. MRI chest, being radiation-free imaging modality can act as an alternative to CT chest in the evaluation of lung changes in patients recovered from COVID-19 pneumonia.

Outlook of various diagnostics and nanodiagnostic techniques for COVID-19

The sudden outbreak of the coronavirus disease 2019 (COVID-19) pandemic has brought to the fore the existing threat of disease-causing pathogens that affect public health all over the world. It has left the best healthcare systems struggling to contain the spread of disease and its consequences. Under challenging circumstances, several innovative technologies have emerged that facilitated quicker diagnosis and treatment. Nanodiagnostic devices are biosensing platforms developed using nanomaterials such as nanoparticles, nanotubes, nanowires, etc. These devices have the edge over conventional techniques such as reverse transcription-polymerase chain reaction (RT-PCR) because of their ease of use, quicker analysis, possible miniaturization, and scope for use in point-of-care (POC) treatment. This review discusses the techniques currently used for COVID-19 diagnosis, emphasizing nanotechnology-based diagnostic devices. The commercialized nanodiagnostic devices in various research and development stages are also reviewed. The advantages of nanodiagnostic devices over other techniques are discussed, along with their limitations. Additionally, the important implications of the utility of nanodiagnostic devices in COVID-19, their prospects for future development for use in clinical and POC settings, and personalized healthcare are also discussed.

Towards smart diagnostic methods for COVID-19: Review of deep learning for medical imaging

The infectious disease known as COVID-19 has spread dramatically all over the world since December 2019. The fast diagnosis and isolation of infected patients are key factors in slowing down the spread of this virus and better management of the pandemic. Although the CT and X-ray modalities are commonly used for the diagnosis of COVID-19, identifying COVID-19 patients from medical images is a time-consuming and error-prone task. Artificial intelligence has shown to have great potential to speed up and optimize the prognosis and diagnosis process of COVID-19. Herein, we review publications on the application of deep learning (DL) techniques for diagnostics of patients with COVID-19 using CT and X-ray chest images for a period from January 2020 to October 2021. Our review focuses solely on peer-reviewed, well-documented articles. It provides a comprehensive summary of the technical details of models developed in these articles and discusses the challenges in the smart diagnosis of COVID-19 using DL techniques. Based on these challenges, it seems that the effectiveness of the developed models in clinical use needs to be further investigated. This review provides some recommendations to help researchers develop more accurate prediction models.

Diagnostic Approaches For COVID-19: Lessons Learned and the Path Forward

Coronavirus disease 2019 (COVID-19) is a transmitted respiratory disease caused by the infection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although humankind has experienced several outbreaks of infectious diseases, the COVID-19 pandemic has the highest rate of infection and has had high levels of social and economic repercussions. The current COVID-19 pandemic has highlighted the limitations of existing virological tests, which have failed to be adopted at a rate to properly slow the rapid spread of SARS-CoV-2. Pandemic preparedness has developed as a focus of many governments around the world in the event of a future outbreak. Despite the largely widespread availability of vaccines, the importance of testing has not diminished to monitor the evolution of the virus and the resulting stages of the pandemic. Therefore, developing diagnostic technology that serves as a line of defense has become imperative. In particular, that test should satisfy three criteria to be widely adopted: simplicity, economic feasibility, and accessibility. At the heart of it all, it must enable early diagnosis in the course of infection to reduce spread. However, diagnostic manufacturers need guidance on the optimal characteristics of a virological test to ensure pandemic preparedness and to aid in the effective treatment of viral infections. Nanomaterials are a decisive element in developing COVID-19 diagnostic kits as well as a key contributor to enhance the performance of existing tests. Our objective is to develop a profile of the criteria that should be available in a platform as the target product. In this work, virus detection tests were evaluated from the perspective of the COVID-19 pandemic, and then we generalized the requirements to develop a target product profile for a platform for virus detection.

CVD-HNet: Classifying Pneumonia and COVID-19 in Chest X-ray Images Using Deep Network

The use of computer-assisted analysis to improve image interpretation has been a long-standing challenge in the medical imaging industry. In terms of image comprehension, Continuous advances in AI (Artificial Intelligence), predominantly in DL (Deep Learning) techniques, are supporting in the classification, Detection, and quantification of anomalies in medical images. DL techniques are the most rapidly evolving branch of AI, and it's recently been successfully pragmatic in a variety of fields, including medicine. This paper provides a classification method for COVID 19 infected X-ray images based on new novel deep CNN model. For COVID19 specified pneumonia analysis, two new customized CNN architectures, CVD-HNet1 (COVID-HybridNetwork1) and CVD-HNet2 (COVID-HybridNetwork2), have been designed. The suggested method utilizes operations based on boundaries and regions, as well as convolution processes, in a systematic manner. In comparison to existing CNNs, the suggested classification method achieves excellent Accuracy 98 percent, F Score 0.99 and MCC 0.97. These results indicate impressive classification accuracy on a limited dataset, with more training examples, much better results can be achieved. Overall, our CVD-HNet model could be a useful tool for radiologists in diagnosing and detecting COVID 19 instances early.

Deep learning-based convolutional neural network for intramodality brain MRI synthesis

PURPOSE

The existence of multicontrast magnetic resonance (MR) images increases the level of clinical information available for the diagnosis and treatment of brain cancer patients. However, acquiring the complete set of multicontrast MR images is not always practically feasible. In this study, we developed a state-of-the-art deep learning convolutional neural network (CNN) for image-to-image translation across three standards MRI contrasts for the brain.

METHODS

BRATS'2018 MRI dataset of 477 patients clinically diagnosed with glioma brain cancer was used in this study, with each patient having T1-weighted (T1), T2-weighted (T2), and FLAIR contrasts. It was randomly split into 64%, 16%, and 20% as training, validation, and test set, respectively. We developed a U-Net model to learn the nonlinear mapping of a source image contrast to a target image contrast across three MRI contrasts. The model was trained and validated with 2D paired MR images using a mean-squared error (MSE) cost function, Adam optimizer with 0.001 learning rate, and 120 epochs with a batch size of 32. The generated synthetic-MR images were evaluated against the ground-truth images by computing the MSE, mean absolute error (MAE), peak signal-to-noise ratio (PSNR), and structural similarity index (SSIM).

RESULTS

The generated synthetic-MR images with our model were nearly indistinguishable from the real images on the testing dataset for all translations, except synthetic FLAIR images had slightly lower quality and exhibited loss of details. The range of average PSNR, MSE, MAE, and SSIM values over the six translations were 29.44-33.25 dB, 0.0005-0.0012, 0.0086-0.0149, and 0.932-0.946, respectively. Our results were as good as the best-reported results by other deep learning models on BRATS datasets.

CONCLUSIONS

Our U-Net model exhibited that it can accurately perform image-to-image translation across brain MRI contrasts. It could hold great promise for clinical use for improved clinical decision-making and better diagnosis of brain cancer patients due to the availability of multicontrast MRIs. This approach may be clinically relevant and setting a significant step to efficiently fill a gap of absent MR sequences without additional scanning.

Inter-Observer Agreement between Low-Dose and Standard-Dose CT with Soft and Sharp Convolution Kernels in COVID-19 Pneumonia

Computed tomography (CT) has been an essential diagnostic tool during the COVID-19 pandemic. The study aimed to develop an optimal CT protocol in terms of safety and reliability. For this, we assessed the inter-observer agreement between CT and low-dose CT (LDCT) with soft and sharp kernels using a semi-quantitative severity scale in a prospective study (Moscow, Russia). Two consecutive scans with CT and LDCT were performed in a single visit. Reading was performed by ten radiologists with 3–25 years’ experience. The study included 230 patients, and statistical analysis showed LDCT with a sharp kernel as the most reliable protocol (percentage agreement 74.35 ± 43.77%), but its advantage was marginal. There was no significant correlation between radiologists’ experience and average percentage agreement for all four evaluated protocols. Regarding the radiation exposure, CTDI_vol was 3.6 ± 0.64 times lower for LDCT. In conclusion, CT and LDCT with soft and sharp reconstructions are equally reliable for COVID-19 reporting using the “CT 0-4” scale. The LDCT protocol allows for a significant decrease in radiation exposure but may be restricted by body mass index.

COVID-19 in Children: Update on Diagnosis and Management

In December 2019, a new infectious disease called coronavirus disease 2019 (COVID-19) attributed to the new virus named severe scute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected. The gold standard for the diagnosis of SARS-CoV-2 infection is the viral identification in nasopharyngeal swab by real-time polymerase chain reaction. Few data on the role of imaging are available in the pediatric population. Similarly, considering that symptomatic therapy is adequate in most of the pediatric patients with COVID-19, few pediatric pharmacological studies are available. The main aim of this review is to describe and discuss the scientific literature on various imaging approaches and therapeutic management in children and adolescents affected by COVID-19. Clinical manifestations of COVID-19 are less severe in children than in adults and as a consequence the radiologic findings are less marked. If imaging is needed, chest radiography is the first imaging modality of choice in the presence of moderate-to-severe symptoms. Regarding therapy, acetaminophen or ibuprofen are appropriate for the vast majority of pediatric patients. Other drugs should be prescribed following an appropriate individualized approach. Due to the characteristics of COVID-19 in pediatric age, the importance of strengthening the network between hospital and territorial pediatrics for an appropriate diagnosis and therapeutic management represents a priority.